Understand European GMPs and the Role of the QP

7 - 8 June 2011, Washington D.C. Metro Area, USA.
With optional Post-Conference Sessions on June 9, 2011.
Over the past few years the role and duties of the Qualified Person keep increasing in significance and scope. Being the key person in the quality function of a pharmaceutical company, the QP has to consider many issues to fulfil the responsibilities and to comply with the European legislation.

This Conference is designed by QPs and international Experts as a forum with focus on sharing information and experience and on discussing the critical areas of European GMPs and the QP's daily work.

The Conference has been designed for non-European QA and QCU personnel, upper management functions and authority representatives who want to be informed about the latest development regarding European GMPs and the duties and responsibilities of Qualified Persons.

Speakers:

  • Richard M. Bonner, Qualified Person, Formerly with Eli Lilly and Company Ltd., UK
  • Dr Christopher Burgess, Qualified Person, Burgess Analytical Consultancy, UK
  • Dr Dimitrios Catsoulacos, European Medicines Agency, EMA
  • Dr Bernd Renger, Qualified Person, Chairman, European QP Association
  • Dr Janice Soreth, FDA, Office of International Programs at EMA
  • Martine Tratsaert, Qualified Person, Johnson & Johnson, Belgium
  • Mark Tucker, Ph.D., Genentech Inc./Roche Group, USA

Highlights
Understand European GMPs

  • ƒ The European Pharmaceutical Legislation
  • ƒƒ Import/ Export, CEPs and GMP Certificates
  • ƒƒ EU Product Quality Review Requirements versus US Annual Report Requirements

Understand the Role of the QP

    ƒƒ
  • The Legal and Professional Duties of the Qualified Person
  • ƒ EU Inspections in the U.S. and the Involvement of the QP
  • ƒƒ The EU Discretion Paper and the Release of Batches by the QP
  • ƒƒ The Role of the QP in Contract Manufacturing
  • ƒƒ The role of the QP in the Supply Chain and Supplier Qualification
  • ƒƒ The US Quality Unit versus the EU QP

The view of FDA and EMA
With optional Post-Conference Sessions on June 9, 2011

  • ƒƒ Session 1: Case studies: Certification by a QP and Batch Release
  • ƒƒ Session 2: Clinical Trial Supplies: IMP Handling in Europe and the Role of the QP

For further information and registration, please visit:
http://www.gmp-compliance.org/qpag_forum_5.html

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Researchers call for worldwide biosurveillance net…

The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding th...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

New study supports remdesivir as COVID-19 treatmen…

The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies in the battle against COVI…

An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have ...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara® (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...